Biocryst Pharmaceuticals‘ once-daily oral therapy Orladeyo (berotralstat) is now approved in Japan to prevent swelling attacks in children with hereditary angioedema (HAE) as young as 2 years old. Japan’s Ministry of Health, Labor and Welfare (MHLW) first approved Orladeyo in 2021 as a treatment for HAE…
Discussion
Onvuzosiran, an experimental treatment for hereditary angioedema (HAE) now in Phase 3 testing, has been granted fast track designation from the U.S. Food and Drug Administration (FDA). The FDA grants this status to expedite the development and review of experimental medicines that show potential to address unmet medical needs…
Discussion
Long-term preventive treatment with Takhzyro (lanadelumab-flyo) — approved in the U.S. and the European Union for nearly a decade — substantially reduces the rate of swelling attacks in people with hereditary angioedema (HAE) treated in routine clinical practice. That’s according to the final results of a Phase 4 study…
Discussion
An infant with recurrent episodes of swelling in her limbs and around her eyes was ultimately diagnosed with idiopathic angioedema after tests ruled out lymphedema and other potential causes, according to a case report. The 4-month-old girl was initially referred for evaluation for possible lymphedema, a condition in which…
Angioedema is the formal medical term for swelling under the skin. It usually occurs as part of an allergic reaction, but has forms that are not due to allergies.
Acute angioedema often occurs as part of an allergic reaction to various allergens or triggers. These can include certain foods, insect bites or stings, medications, and natural rubber products like latex.
Angioedema and hives often occur at the same time. However, angioedema causes large, thick welts which may not be itchy, whereas hives are smaller and usually itchy.
Get regular updates to your inbox.
